37 related articles for article (PubMed ID: 18560232)
1. Effects of Body Mass Index on Hypertriglyceridemia Associated with Oral Bexarotene Therapy: A Post Hoc Analysis of an Open-Label Comparative Clinical Study of Combined Bexarotene and Phototherapy Versus Bexarotene Monotherapy for Japanese Patients with Cutaneous T-Cell Lymphoma.
Sanagawa A; Hayakawa T; Yamamoto A; Hotta Y; Furukawa-Hibi Y; Morita A
Drugs R D; 2024 Jun; ():. PubMed ID: 38871976
[TBL] [Abstract][Full Text] [Related]
2. Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer.
Thomas PS; Patel AB; Lee JJ; Liu DD; Hernandez M; Muzzio M; Contreras A; Sepeda V; Mays C; Weber D; Vornik LA; Khan SA; Dimond E; Heckman-Stoddard BM; Perloff M; Brown PH
Cancer Prev Res (Phila); 2023 Jan; 16(1):47-55. PubMed ID: 36228112
[TBL] [Abstract][Full Text] [Related]
3. Melatonin May Increase Anticancer Potential of Pleiotropic Drugs.
Bojková B; Kubatka P; Qaradakhi T; Zulli A; Kajo K
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30563247
[TBL] [Abstract][Full Text] [Related]
4. A phase I/II study of bexarotene with carboplatin and weekly paclitaxel for the treatment of patients with advanced non-small cell lung cancer.
Dragnev KH; Whyman JD; Hahn CK; Kebbekus PE; Kokko SF; Bhatt SM; Rigas JR
J Thorac Dis; 2018 Sep; 10(9):5531-5537. PubMed ID: 30416803
[TBL] [Abstract][Full Text] [Related]
5. The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention.
Peters JM; Shah YM; Gonzalez FJ
Nat Rev Cancer; 2012 Feb; 12(3):181-95. PubMed ID: 22318237
[TBL] [Abstract][Full Text] [Related]
6. PPAR gamma, bioactive lipids, and cancer progression.
Robbins GT; Nie D
Front Biosci (Landmark Ed); 2012 Jan; 17(5):1816-34. PubMed ID: 22201838
[TBL] [Abstract][Full Text] [Related]
7. Cancer risk in type 2 diabetes mellitus: metabolic links and therapeutic considerations.
Sun G; Kashyap SR
J Nutr Metab; 2011; 2011():708183. PubMed ID: 21773024
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinase and G protein coupled receptors: co-conspirators in the pathogenesis of autoimmune disease and cancer.
Eck SM; Blackburn JS; Schmucker AC; Burrage PS; Brinckerhoff CE
J Autoimmun; 2009; 33(3-4):214-21. PubMed ID: 19800199
[TBL] [Abstract][Full Text] [Related]
9. Obesity and breast cancer: the roles of peroxisome proliferator-activated receptor-γ and plasminogen activator inhibitor-1.
Carter JC; Church FC
PPAR Res; 2009; 2009():345320. PubMed ID: 19672469
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of docetaxel and oxaliplatin for second-line treatment of urothelial carcinoma.
Srinivas S; Harshman LC
Chemotherapy; 2009; 55(5):321-6. PubMed ID: 19641314
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
Kannangara AP; Levitan D; Fleischer AB
J Dermatolog Treat; 2009; 20(3):169-76. PubMed ID: 19016373
[TBL] [Abstract][Full Text] [Related]
12. Bexarotene: a clinical review.
Farol LT; Hymes KB
Expert Rev Anticancer Ther; 2004 Apr; 4(2):180-8. PubMed ID: 15056048
[TBL] [Abstract][Full Text] [Related]
13. Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion.
Assaf C; Bagot M; Dummer R; Duvic M; Gniadecki R; Knobler R; Ranki A; Schwandt P; Whittaker S
Br J Dermatol; 2006 Aug; 155(2):261-6. PubMed ID: 16882161
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of bexarotene and rosiglitazone in patients with refractory cancers.
Read WL; Baggstrom MQ; Fracasso PM; Govindan R
Chemotherapy; 2008; 54(3):236-41. PubMed ID: 18560232
[TBL] [Abstract][Full Text] [Related]
15. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.
Duvic M; Martin AG; Kim Y; Olsen E; Wood GS; Crowley CA; Yocum RC;
Arch Dermatol; 2001 May; 137(5):581-93. PubMed ID: 11346336
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia.
Tsai DE; Luger SM; Andreadis C; Vogl DT; Kemner A; Potuzak M; Goradia A; Loren AW; Perl AE; Schuster SJ; Porter DL; Stadtmauer EA; Goldstein SC; Thompson JE; Swider C; Bagg A; Mato AR; Carroll M
Clin Cancer Res; 2008 Sep; 14(17):5619-25. PubMed ID: 18765556
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
